Merck announces recipients of third annual €1 million ‘Grant for Oncology Innovation’ award
Grant established by Merck recognizes pioneering research in personalized treatment of solid tumours.
Merck has announced the recipients of the 2016 Grant for Oncology Innovation (GOI), who will share a €1 million grant to progress their respective research initiatives. The winners were formally awarded at an award presentation coinciding with the 2016 annual European Society of Medical Oncology (ESMO) Congress in Copenhagen, Denmark.
The three winning proposals, which focus on breast cancer, colorectal cancer and lung cancer, were selected from a total of 405 applications representing 49 countries, following a comprehensive review by an expert scientific steering committee made up of internationally renowned oncologists.
The 2016 GOI winners are
• Alberto Bardelli, University of Torino, Italy, for his proposal: ‘Heterogeneity and clonal evolution as a therapeutic opportunity for colorectal cancers’
• Enriqueta Felip, Vall d’Hebron Institute of Oncology, Spain, for her proposal: ‘New technologies for new treatments: liquid biopsy meets immunotherapy’
• Dr Dongxu Liu, Auckland University of Technology, New Zealand for his proposal: ‘How does SHON* expression in tumors determine the efficacy of endocrine therapy in breast cancer?’
“The Grant for Oncology Innovation is an example of Merck’s commitment to scientific innovation in oncology. We are proud to support pioneering work that pushes the boundaries of creativity and science in order to deliver transformative innovation with a potential to improve the lives of cancer patients in the near-term future,” said Dr Steven Hildemann, Global Chief Medical Officer and Head of Global Medical and Safety at Merck´s Biopharma business. “We are honored to recognize these talented and inspiring researchers and to play a role in enabling these innovative projects to become a reality.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance